FDA Approves First Long-Term Implantable Continuous Glucose Monitor

June 21, 2018. The US Food and Drug Administration has approved the Eversense Continuous Glucose Monitor (CGM) System by Senseonics, which is the first long-term (up to 90 days) implantable CGM. The device is implanted subcutaneously in the patient’s upper arm under local anesthesia. Glucose data, stored in a HIPAA-compliant cloud, are transmitted to the user’s mobile phone via Bluetooth. The device is approved for patients aged 18 years and older with type 1 or type 2 diabetes and should be used in addition to fingerstick blood glucose monitoring. Read more here.